only with
Torrent Pharmaceuticals Ltd.
Torrent Pharma
Torrent Pharmaceuticals Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Large-cap - With a market cap of ₹1772.51 Cr.
| EX-Date | Purpose |
|---|---|
| 18 05 2021 | Audited Results & Final Dividend Inter alia, the Board would also consider the following: i. Payment of Final Dividend for the year 2020-21. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders approval in the ensuing Annual General Meetin |
| 27 07 2021 | Quarterly Results |
| 26 10 2021 | Quarterly Results |
| 25 01 2022 | Quarterly Results & Interim Dividend |
| 25 05 2022 | Final Dividend & Bonus issue & Audited Results |
| 29 07 2022 | Quarterly Results |
| 21 10 2022 | Quarterly Results |
| 25 01 2023 | Quarterly Results & Interim Dividend |
| 30 05 2023 | Final Dividend & Audited Results |
| 07 08 2023 | Quarterly Results |
| 23 10 2023 | Quarterly Results |
| 02 02 2024 | Quarterly Results & Interim Dividend |
| 25 10 2024 | Quarterly Results |
| 24 01 2025 | Quarterly Results & Interim Dividend |
| 20 05 2025 | Final Dividend & Audited Results |
| 28 07 2025 | Quarterly Results & Inter alia, will also consider the Issue of Unsecured or Secured Redeemable Non Convertible Debentures or Bonds by way of private placement. |
| 07 11 2025 | Quarterly Results |
| 05 01 2026 | Inter alia, to consider and approve the proposal for issuance of secured Non-Convertible Debentures on private placement basis within the limits approved by the Board of Directors of the Company at its meeting held on 28-Jul-25 |
| 13 02 2026 | Quarterly Results & Interim Dividend |
| 22 05 2026 | Fund Raising & Final Dividend & Audited Results |
| 30 07 2026 | Quarterly Results |
| 23 10 2026 | Quarterly Results & Audited Results |
News
Torrent Pharmaceuticals submits analyst meet intimation
Torrent Pharma reports marginal rise in Q1 consolidated net profit
Consolidated total income of the company has increased 56.29% at Rs 4,909 crore for Q1FY27
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 4920.00 Mln, in the June 2026 quarter
Torrent Pharmaceuticals informs about updates
Torrent Pharmaceuticals informs about ESG rating
Torrent Pharmaceuticals informs about board meeting
Torrent Pharma jumps despite consolidated net profit falls 22% in Q4
The total consolidated income of the company has increased by 42.13% at Rs 4,180.00 crore for Q4FY26
Torrent Pharma’s consolidated net profit falls 22% in Q4
The total consolidated income of the company has increased by 42.13% at Rs 4,180.00 crore for Q4FY26
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 4670.00 Mln, in the March 2026 quarter
USFDA concludes inspection at Torrent Pharmaceuticals’ Bileshwarpura facility
The inspection has been concluded with zero observation
Torrent Pharmaceuticals launches Semaglutide brands in India
The launch expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 5770.00 Mln, in the December 2025 quarter
Torrent Pharmaceuticals informs about board meeting
Torrent Pharmaceuticals rises on acquiring stake in JB Chemicals
Following the aforesaid acquisition, the company holds an aggregate of 7,82,65,402 equity shares of JB Chemicals
Torrent Pharmaceuticals acquires stake in JB Chemicals
Following the aforesaid acquisition, the company holds an aggregate of 7,82,65,402 equity shares of JB Chemicals
Torrent Pharma moves up on getting nod to raise upto Rs 12,500 crore through NCDs
Securities Transfer and Stakeholders Relationship Committee has at its meeting held on January 05, 2026 has approved the same
Torrent Pharmaceuticals gets nod to raise upto Rs 12,500 crore through NCDs
Securities Transfer and Stakeholders Relationship Committee has at its meeting held on January 05, 2026 has approved the same
Torrent Pharmaceuticals informs about credit rating
Torrent Pharmaceuticals zooms on reporting 30% rise in Q2 consolidated net profit
The consolidated total income of the company increased by 13.99% at Rs 3,275 crore for Q2FY26
Torrent Pharmaceuticals reports 30% rise in Q2 consolidated net profit
The consolidated total income of the company increased by 13.99% at Rs 3,275 crore for Q2FY26
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 5970.00 Mln, in the September 2025 quarter
torrent Pharmaceuticals informs about board meeting
Torrent Pharmaceuticals informs about credit rating
Torrent Pharmaceuticals informs about redemption of CP
Torrent Pharmaceuticals enters into agreement to subscribe 26% stake in Torrent Urja 27
The said acquisition is expected to be completed in 18 to 20 months
Torrent Pharmaceuticals informs about disclosure
Torrent Pharmaceuticals soars on reporting 20% rise in Q1 consolidated net profit
The total consolidated income of the company increased by 8.95% at Rs 3,141 crore for Q1FY26
Torrent Pharmaceuticals informs about financial results
Torrent Pharmaceuticals reports 20% rise in Q1 consolidated net profit
The total consolidated income of the company increased by 8.95% at Rs 3,141 crore for Q1FY26
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 5510.00 Mln, in the June 2025 quarter
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharmaceuticals gains on seeking CCI’s nod to acquire majority stake in J B Chemicals
After the completion of the deal, Torrent Pharmaceuticals will become India’s second most valued pharma company
Torrent Pharmaceuticals seeks CCI’s nod to acquire majority stake in J B Chemicals
After the completion of the deal, Torrent Pharmaceuticals will become India’s second most valued pharma company
Torrent Pharma surges on executing SPA to acquire 2.41% stake in J.B. Chemicals & Pharmaceuticals
The company has executed share purchase agreement with employees of the J.B. Chemicals & Pharmaceuticals
Torrent Pharma executes SPA to acquire 2.41% stake in J.B. Chemicals & Pharmaceuticals
The company has executed share purchase agreement with employees of the J.B. Chemicals & Pharmaceuticals
Torrent Pharmaceuticals informs about teleconference
Torrent Pharmaceuticals gains on inking pact to acquire controlling stake in JB Pharma
The company will acquire 46.39% equity stake of JB Pharma through a SPA at a consideration of Rs 11,917 crore
Torrent Pharmaceuticals to acquire controlling stake in JB Pharma
The company will acquire 46.39% equity stake of JB Pharma through a SPA at a consideration of Rs 11,917 crore
Torrent Pharmaceuticals surges on raising Rs 300 crore through Commercial Papers
Maturity of the said Commercial Papers will be on September 26, 2025
Torrent Pharmaceuticals raises Rs 300 crore through Commercial Papers
Maturity of the said Commercial Papers will be on September 26, 2025
Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers
Tenure of the instrument is 90 days
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 4740.00 Mln, in the March 2025 quarter
Torrent Pharma - Quaterly Results
Torrent Pharmaceuticals informs about trading window closure
Torrent Pharmaceuticals informs about outcome of board meeting
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 4850.00 Mln, in the December 2024 quarter
Torrent Pharmaceuticals raises Rs 200 crore through commercial papers
Maturity of the said Commercial Papers will be on March 26, 2025
Torrent Pharma rises on entering into agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India
Torrent Pharma enters into agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 4600.00 Mln, in the September 2024 quarter
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharmaceuticals trades in green on incorporating Wholly owned subsidiary in Chile
Torrent Pharma Chile is incorporated with the object of providing business support to the company in the relevant jurisdiction
Torrent Pharmaceuticals incorporates Wholly owned subsidiary in Chile
Torrent Pharma Chile is incorporated with the object of providing business support to the company in the relevant jurisdiction
Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers
The company has issued CPs at interest rate of 7.32% per annum
USFDA issues EIR to Torrent Pharmaceuticals’ Gujarat facility
USFDA has now successfully concluded inspection at Torrent Pharmaceuticals’ Oral-Oncology manufacturing facility
Torrent Pharmaceuticals hits 52-week high on reporting 52% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 8.79% at Rs 2699 crore for Q3FY24
Torrent Pharmaceuticals reports 52% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 8.79% at Rs 2699 crore for Q3FY24
Torrent Pharmaceuticals informs about presentation
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 2970.00 Mln, in the December 2023 quarter
Torrent Pharmaceuticals informs about board meeting
Torrent Pharmaceuticals incorporates Wholly Owned Subsidiary in Colombia
Torrent Colombia is incorporated with the object of providing business support to the Company in the relevant jurisdiction
USFDA concludes pre-approval inspection at Torrent Pharmaceuticals’ Gujarat facility
At the end of the inspection, the Company was issued a Form 483 with 5 procedural observations
Torrent Pharmaceuticals informs about press release
Torrent Pharmaceuticals informs about press release
Torrent Pharmaceuticals enters into licensing and supply agreement with Zydus Lifesciences
With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden and offers greater convenience for patients
Torrent Pharmaceuticals informs about issuance of duplicate share certificates
Torrent Pharmaceuticals informs about transcript of conference call
Torrent Pharmaceuticals zooms on reporting 24% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 16.43% at Rs 2,686 crore for Q2FY24
Torrent Pharmaceuticals reports 24% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 16.43% at Rs 2,686 crore for Q2FY24
Torrent Pharma reports Profit after tax of Rs 3270.00 Mln, in the September 2023 quarter
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharmaceuticals informs about issuance of duplicate share certificates
Torrent Pharmaceuticals informs about press release
Torrent Pharmaceuticals moves up on getting EIR for Dahej manufacturing facility
USFDA had conducted inspection at the said manufacturing facility from May 17, 2023 to May 25, 2023
Torrent Pharmaceuticals gets EIR for Dahej manufacturing facility
Earlier, USFDA had conducted inspection at the said manufacturing facility from May 17, 2023 to May 25, 2023
Torrent Pharmaceuticals informs about disclosure
Torrent Pharma - Quaterly Results
Torrent Pharma reports Profit after tax of Rs 3230.00 Mln, in the June 2023 quarter
Torrent Pharmaceuticals informs about annual report
Torrent Pharmaceuticals rises on getting EIR for Gujarat Oral-Oncology manufacturing facility
The inspection has now been successfully closed by the USFDA
Torrent Pharmaceuticals gets EIR for Gujarat Oral-Oncology manufacturing facility
The inspection has now been successfully closed by the USFDA
Torrent Pharmaceuticals informs about conference call transcript
Torrent Pharmaceuticals shines on planning to raise up to Rs 5,000 crore
The Board of Directors of the company in its meeting held on May 30, 2023 has recommended to the members to obtain enabling approval for the same
Torrent Pharma reports Profit after tax of Rs 2190.00 Mln, in the March 2023 quarter
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharmaceuticals informs about teleconference
Torrent Pharmaceuticals informs about board meeting
Torrent Pharmaceuticals informs about loss of share certificates
Torrent Pharmaceuticals declines on getting 1 observation from USFDA for Gujarat facility
At the end of the inspection, the company has been issued a ‘Form 483’ with 1 observation, which is procedural in nature
USFDA concludes pre-approval inspection at Torrent Pharmaceuticals’ Gujarat facility
At the end of the inspection, the company has been issued a ‘Form 483’ with 1 observation, which is procedural in nature
Torrent Pharmaceuticals informs about newspaper publication
Torrent Pharmaceuticals informs about analyst meet
Torrent Pharmaceuticals forays into OTC segment with calcium supplement brand
The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body
Torrent Pharmaceuticals reports 14% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 15.07% to Rs 2481 crore for Q3FY23
Torrent Pharma reports Profit after tax of Rs 2290.00 Mln, in the December 2022 quarter
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
Torrent Pharma - Quaterly Results
JB Chemicals, Dilip Buildcon and Torrent Pharmaceuticals to see some action today
IRIS Business Services has received Letter of Intent from the Royal Monetary Authority of Bhutan
Torrent Pharmaceuticals informs about press release
Torrent Pharmaceuticals enters into partnership with Boehringer Ingelheim India
Empagliflozin is a novel sodium glucose co-transporter-2 inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus
Torrent Pharmaceuticals informs about investors meet
Torrent Pharmaceuticals trades higher on raising Rs 500 crore through NCDs
Date of maturity of said NCDs will be 7 years from date of allotment
Torrent Pharmaceuticals raises Rs 500 crore through NCDs
Date of maturity of said NCDs will be 7 years from date of allotment
Torrent Pharmaceuticals informs about credit rating
Torrent Pharma - Quaterly Results
Torrent Pharmaceuticals informs about conference call with analyst meet
USFDA concludes inspection at Torrent Pharmaceuticals’ Gujarat manufacturing facility
The USFDA inspected facility from September 19, 2022 to September 28, 2022
Torrent Pharmaceutical informs about closure of trading window
Torrent Pharmaceuticals inks pacts to acquire 100% stake in Curatio
The transaction is subject to conditions precedent and is expected to close within one month’s time
Torrent Pharma rises on getting long term credit rating upgraded by ICRA
ICRA has reaffirmed its rating on commercial paper programme at ‘Al+’
ICRA upgrades Torrent Pharma’s long term credit rating to ‘AA+/Stable’
ICRA has reaffirmed its rating on commercial paper programme at ‘Al+’
Torrent Pharmaceuticals informs about clarification
Torrent Pharmaceuticals informs about allotment of equity shares
Torrent Pharmaceuticals informs about press release
Torrent Pharma rises on entering into agreement with Dr Reddy’s Laboratories
The complete integration and transition of the brands are expected to be completed by June 2022
Torrent Pharma enters into agreement with Dr Reddy’s Laboratories
The complete integration and transition of the brands are expected to be completed by June 2022